Cargando…

Reduced drug incorporation into DNA and antiapoptosis as the crucial mechanisms of resistance in a novel nelarabine-resistant cell line

BACKGROUND: Nine-beta-D-arabinofuranosylguanine (ara-G), an active metabolite of nelarabine, enters leukemic cells through human Equilibrative Nucleoside Transporter 1, and is then phosphorylated to an intracellular active metabolite ara-G triphosphate (ara-GTP) by both cytosolic deoxycytidine kinas...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamauchi, Takahiro, Uzui, Kanako, Nishi, Rie, Shigemi, Hiroko, Ueda, Takanori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4122765/
https://www.ncbi.nlm.nih.gov/pubmed/25070259
http://dx.doi.org/10.1186/1471-2407-14-547
_version_ 1782329387688919040
author Yamauchi, Takahiro
Uzui, Kanako
Nishi, Rie
Shigemi, Hiroko
Ueda, Takanori
author_facet Yamauchi, Takahiro
Uzui, Kanako
Nishi, Rie
Shigemi, Hiroko
Ueda, Takanori
author_sort Yamauchi, Takahiro
collection PubMed
description BACKGROUND: Nine-beta-D-arabinofuranosylguanine (ara-G), an active metabolite of nelarabine, enters leukemic cells through human Equilibrative Nucleoside Transporter 1, and is then phosphorylated to an intracellular active metabolite ara-G triphosphate (ara-GTP) by both cytosolic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. Ara-GTP is subsequently incorporated into DNA, thereby inhibiting DNA synthesis. METHODS: In the present study, we developed a novel ara-G-resistant variant (CEM/ara-G) of human T-lymphoblastic leukemia cell line CCRF-CEM, and elucidated its mechanism of ara-G resistance. The cytotoxicity was measured by using the growth inhibition assay and the induction of apoptosis. Intracellular triphosphate concentrations were quantitated by using HPLC. DNA synthesis was evaluated by the incorporation of tritiated thymidine into DNA. Protein expression levels were determined by using Western blotting. RESULTS: CEM/ara-G cells were 70-fold more ara-G-resistant than were CEM cells. CEM/ara-G cells were also refractory to ara-G-mediated apoptosis. The transcript level of human Equilibrative Nucleoside Transporter 1 was lowered, and the protein levels of deoxycytidine kinase and deoxyguanosine kinase were decreased in CEM/ara-G cells. The subsequent production of intracellular ara-GTP (21.3 pmol/10(7) cells) was one-fourth that of CEM cells (83.9 pmol/10(7) cells) after incubation for 6 h with 10 μM ara-G. Upon ara-G treatment, ara-G incorporation into nuclear and mitochondrial DNA resulted in the inhibition of DNA synthesis of both fractions in CEM cells. However, DNA synthesis was not inhibited in CEM/ara-G cells due to reduced ara-G incorporation into DNA. Mitochondrial DNA-depleted CEM cells, which were generated by treating CEM cells with ethidium bromide, were as sensitive to ara-G as CEM cells. Anti-apoptotic Bcl-xL was increased and pro-apoptotic Bax and Bad were reduced in CEM/ara-G cells. CONCLUSIONS: An ara-G-resistant CEM variant was successfully established. The mechanisms of resistance included reduced drug incorporation into nuclear DNA and antiapoptosis.
format Online
Article
Text
id pubmed-4122765
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-41227652014-08-07 Reduced drug incorporation into DNA and antiapoptosis as the crucial mechanisms of resistance in a novel nelarabine-resistant cell line Yamauchi, Takahiro Uzui, Kanako Nishi, Rie Shigemi, Hiroko Ueda, Takanori BMC Cancer Research Article BACKGROUND: Nine-beta-D-arabinofuranosylguanine (ara-G), an active metabolite of nelarabine, enters leukemic cells through human Equilibrative Nucleoside Transporter 1, and is then phosphorylated to an intracellular active metabolite ara-G triphosphate (ara-GTP) by both cytosolic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. Ara-GTP is subsequently incorporated into DNA, thereby inhibiting DNA synthesis. METHODS: In the present study, we developed a novel ara-G-resistant variant (CEM/ara-G) of human T-lymphoblastic leukemia cell line CCRF-CEM, and elucidated its mechanism of ara-G resistance. The cytotoxicity was measured by using the growth inhibition assay and the induction of apoptosis. Intracellular triphosphate concentrations were quantitated by using HPLC. DNA synthesis was evaluated by the incorporation of tritiated thymidine into DNA. Protein expression levels were determined by using Western blotting. RESULTS: CEM/ara-G cells were 70-fold more ara-G-resistant than were CEM cells. CEM/ara-G cells were also refractory to ara-G-mediated apoptosis. The transcript level of human Equilibrative Nucleoside Transporter 1 was lowered, and the protein levels of deoxycytidine kinase and deoxyguanosine kinase were decreased in CEM/ara-G cells. The subsequent production of intracellular ara-GTP (21.3 pmol/10(7) cells) was one-fourth that of CEM cells (83.9 pmol/10(7) cells) after incubation for 6 h with 10 μM ara-G. Upon ara-G treatment, ara-G incorporation into nuclear and mitochondrial DNA resulted in the inhibition of DNA synthesis of both fractions in CEM cells. However, DNA synthesis was not inhibited in CEM/ara-G cells due to reduced ara-G incorporation into DNA. Mitochondrial DNA-depleted CEM cells, which were generated by treating CEM cells with ethidium bromide, were as sensitive to ara-G as CEM cells. Anti-apoptotic Bcl-xL was increased and pro-apoptotic Bax and Bad were reduced in CEM/ara-G cells. CONCLUSIONS: An ara-G-resistant CEM variant was successfully established. The mechanisms of resistance included reduced drug incorporation into nuclear DNA and antiapoptosis. BioMed Central 2014-07-29 /pmc/articles/PMC4122765/ /pubmed/25070259 http://dx.doi.org/10.1186/1471-2407-14-547 Text en © Yamauchi et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Yamauchi, Takahiro
Uzui, Kanako
Nishi, Rie
Shigemi, Hiroko
Ueda, Takanori
Reduced drug incorporation into DNA and antiapoptosis as the crucial mechanisms of resistance in a novel nelarabine-resistant cell line
title Reduced drug incorporation into DNA and antiapoptosis as the crucial mechanisms of resistance in a novel nelarabine-resistant cell line
title_full Reduced drug incorporation into DNA and antiapoptosis as the crucial mechanisms of resistance in a novel nelarabine-resistant cell line
title_fullStr Reduced drug incorporation into DNA and antiapoptosis as the crucial mechanisms of resistance in a novel nelarabine-resistant cell line
title_full_unstemmed Reduced drug incorporation into DNA and antiapoptosis as the crucial mechanisms of resistance in a novel nelarabine-resistant cell line
title_short Reduced drug incorporation into DNA and antiapoptosis as the crucial mechanisms of resistance in a novel nelarabine-resistant cell line
title_sort reduced drug incorporation into dna and antiapoptosis as the crucial mechanisms of resistance in a novel nelarabine-resistant cell line
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4122765/
https://www.ncbi.nlm.nih.gov/pubmed/25070259
http://dx.doi.org/10.1186/1471-2407-14-547
work_keys_str_mv AT yamauchitakahiro reduceddrugincorporationintodnaandantiapoptosisasthecrucialmechanismsofresistanceinanovelnelarabineresistantcellline
AT uzuikanako reduceddrugincorporationintodnaandantiapoptosisasthecrucialmechanismsofresistanceinanovelnelarabineresistantcellline
AT nishirie reduceddrugincorporationintodnaandantiapoptosisasthecrucialmechanismsofresistanceinanovelnelarabineresistantcellline
AT shigemihiroko reduceddrugincorporationintodnaandantiapoptosisasthecrucialmechanismsofresistanceinanovelnelarabineresistantcellline
AT uedatakanori reduceddrugincorporationintodnaandantiapoptosisasthecrucialmechanismsofresistanceinanovelnelarabineresistantcellline